Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 31, 2026, Arcadia Biociences, Inc. (the "Company") received an expected letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that its stockholders’ equity, as reported in its Quarterly Report on Form 10-Q for the period ended June 30, 2026 (the “Form 10-Q”), did not meet the minimum stockholders’ equity requi…

Results of Operations and Financial Condition. On August 13, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the second quarter and first half of 2026. A copy of the press release is furnished as Exhibit 99.1, and the Company's financial information tables are furnished as Exhibit 99.2, to this Current Report on Form 8-K and are incorporated herein by reference. The information furnished in this Form 8-K, the press release attached as Exh…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 4, 2026, Arcadia Biosciences, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”), which requires listed sec…

The filing is about the compensation arrangements and bonus payments for certain officers, not a management change.

Regulation FD Disclosure. On January 11, 2026, the Company issued a press release disclosing the Private Placement transaction referenced above. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished herein, including Exhibit 99.1 and 99.2, is not deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section. This information will…

Entry into a Material Definitive Agreement. On June 11, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an institutional accredited investor (the “Purchaser”) for the sale and issuance in a private placement (the “Private Placement”) of (i) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to 3,883,496 shares (“Pre-Funded Warrant Shares”) of common stock of the Company (“Common Stock”), (ii) Series A-1 p…

in their entirety. The Pre-Funded Warrants, Investment Options, Option Shares, Placement Agent Investment Options and Placement Agent Option Shares described in

Results of Operations and Financial Condition. On May 14, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter of 2026. A copy of the press release is furnished as Exhibit 99.1, and the Company's financial information tables are furnished as Exhibit 99.2, to this Current Report on Form 8-K and are incorporated herein by reference. The information furnished in this Form 8-K, the press release attached as Exhibit 99.1, and the…

Changes in Registrant’s Certifying Accountant. (a) Dismissal of Independent Registered Public Accounting Firm On March 30, 2026, the audit committee (the “Audit Committee”) of the board of directors of Arcadia Biosciences, Inc. (the “Company”) dismissed Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registered public accounting firm. Deloitte’s audit reports on the Company’s consolidated financial statements for the years ended December 31, 2025 and December 31, 2024 did not…

Results of Operations and Financial Condition. On March 26, 2026 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1, and the Company's annual financial information tables are furnished as Exhibit 99.2, to this Current Report on Form 8-K and are incorporated herein by reference. The information furnished in this Form 8-K, the press release…

Director — Albert D. Bolles, Ph.D., Deborah Carosella: Directors Albert D. Bolles and Deborah Carosella resigned from their positions.

Entry into a Material Definitive Agreement. On January 9, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with certain investors (the “Participating Holders”) pursuant to which such Participating Holders agreed to exercise certain outstanding preferred investment options to purchase an aggregate of 808,595 shares of the Company’s common stock ("Common Stock"). The preferred investment options subject to the Inducement…

Regulation FD Disclosure. On January12, 2026, the Company issued a press release disclosing the Private Placement transaction referenced above. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished in this Item 7.01, including Exhibit 99.1, is not deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act 1934, as amended, or otherwise subject to the liability of that s…

Unregistered Sales of Equity Securities. The information in

Material Modification to Rights of Security Holders. On January 9, 2026, the Company agreed to reduce the exercise price for the Existing Options to $2.575 per share.

Termination of a Material Definitive Agreement As previously disclosed in the reports and other materials previously filed by Arcadia Biosciences, Inc. (the "Company") with the Securities and Exchange Commission (the "Commission"), on December 4, 2024, the Company, Roosevelt Resources, LP, a Texas limited partnership (“Roosevelt”), and certain other parties entered into a Securities Exchange Agreement (the “Exchange Agreement”) providing for the combination of the two companies in an all-stoc…

Results of Operations and Financial Condition. On November 7, 2025 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1, and related third quarter financial information is furnished as Exhibit 99.2, to this Current Report on Form 8-K and are incorporated herein by reference. The information furnished in this Form 8-K, the press release attached as E…

CFO and principal accounting officer — Mark Kawakami: Mr. Kawakami resigned from his roles as CFO and principal accounting officer.

Results of Operations and Financial Condition. On August 14, 2025 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1, and related first quarter financial information is furnished as Exhibit 99.2, to this Current Report on Form 8-K and are incorporated herein by reference. The information furnished in this Form 8-K, the press release attached as Exhibi…

Results of Operations and Financial Condition. On May 8, 2025 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1, and related first quarter financial information is furnished as Exhibit 99.2, to this Current Report on Form 8-K and are incorporated herein by reference. The information furnished in this Form 8-K, the press release attached as Exhibit 99…

Entry into a Material Definitive Agreement. As previously disclosed on a Current Report on Form 8-K filed by Arcadia Biosciences, Inc. (the “Company” or “Arcadia”) with the Securities and Exchange Commission (the “SEC” or the “Commission”) on December 6, 2024, on December 4, 2024, Arcadia, Roosevelt Resources, LP, a Texas limited partnership (“Roosevelt” or the “Partnership”), and certain other parties in their capacity as representatives of the limited partners of Roosevelt, entered into a S…

Entry into a Material Definitive Agreement. On March 28, 2025, Arcadia Biosciences, Inc. (the "Company") entered into an agreement (the "Agreement") with a third party pursuant to which (i) the third party agreed to transfer to the Company all rights and materials relating to certain intellectual property rights and traits that were included in licenses previously granted by the Company to the third party, returning those rights to the Company; (ii) the third party agreed to pay a total of $7…

Results of Operations and Financial Condition. On March 20, 2025 Arcadia Biosciences, Inc. (the “Company”) issued a press release announcing financial results for the fourth quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1, and the Company's annual financial information tables are furnished as Exhibit 99.2, to this Current Report on Form 8-K and are incorporated herein by reference. The information furnished in this Form 8-K, the press release…

and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act’), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing. Arcadia makes no admission as to the materiality of any in…

The filing appears to be a placeholder or incomplete, not detailing any specific management change.